Novartis turns to algorithms developer Anumana to apply AI to cardio conditions
Related Articles
Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
Diagnostic and Interventional Cardiology: Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosisDecember 20, 2022
FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results
Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has received a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for a new…June 21, 2023
AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance
Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.October 02, 2023
Mayo Clinic launches two companies to tap patient data for AI tools
STAT News: Mayo Clinic is launching two new companies as part of its bid to harness patient data and use it to deliver AI-guided care.April 13, 2021